Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Radiation therapy for patients with breast cancer

2.

The self-sacrificing nature of breast cancer cells has been identified as a possible reason for relapse.

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

Products for Intimate Care and Cancer; Boost for Colorectal Cancer Stool Tests; Ultrasonic Biopsy?

5.

A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot